Headlines around Asia

Novo Nordisk GLP-1 obesity drug Wegovy launched in China. Priced at RMB1,264 - 2,463 for 0.69mg and 3.2mg injections, Wegovy was distributed via public hospitals, private hospitals, and retail pharmacies - New Beijing News

Innovant Bio to release TOPO1 Claudin 18.2 antibody-drug conjugate phase 1 during ESMO Asia, to be held in Singapore Dec. 6-8 (company release)

Kelun Biotech ADC SKB501 for solid tumor cleared for investigative new drug study in China (Company release)

Chugai Pharma, Roche’s Japanese subsidiary, uses Artificial Intelligence in antibody design and reported 3,000 times faster compared to current technology (Nikkei)